TrialJAMA dermatology2019

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Melinda J Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.